LTK fusions: A new target emerges in non-small cell lung cancer

Alissa J Cooper; Lecia V Sequist; Ted W Johnson; Jessica J Lin

doi:10.1016/j.ccell.2021.12.012

LTK fusions: A new target emerges in non-small cell lung cancer

Cancer Cell. 2022 Jan 10;40(1):23-25. doi: 10.1016/j.ccell.2021.12.012.

Authors

Alissa J Cooper¹, Lecia V Sequist¹, Ted W Johnson², Jessica J Lin³

Affiliations

¹ Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
² Pfizer Worldwide Research and Development, La Jolla, CA, USA.
³ Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: jjlin1@partners.org.

Abstract

Identification of targetable fusions as oncogenic drivers in non-small cell lung cancer has transformed its diagnostic and therapeutic paradigm. In a recent article in Nature, Izumi et al. report the discovery of CLIP1-LTK fusion as a novel oncogenic driver in lung cancer, targetable using the ALK tyrosine kinase inhibitor lorlatinib.

Publication types

Comment

MeSH terms

Anaplastic Lymphoma Kinase / genetics
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Gene Fusion
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Receptor Protein-Tyrosine Kinases / genetics

Substances

Protein Kinase Inhibitors
Anaplastic Lymphoma Kinase
LTK protein, human
Receptor Protein-Tyrosine Kinases

Grants and funding

R01 CA164273/CA/NCI NIH HHS/United States